Начало › Множествен миелом › Колорадо › Denver
Клинични проучвания за Множествен миелом в Denver, CO
27 проучвания за Множествен миелом търсят участници в обекти в и около Denver (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 2
- Colorado Blood Cancer Institute, Denver
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Набиране на участнициФаза 1
- Colorado Blood Cancer Institute /ID# 280275, Denver
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Набиране на участнициФаза 3
- Research Site, Denver
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Набиране на участнициФаза 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 3
- Colorado Blood Cancer Institute, Denver
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Набиране на участнициФаза 2
- Colorado Blood Cancer Institute, Denver
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Набиране на участнициФаза 1
- Research Site, Denver
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Набиране на участнициФаза 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 3
- Colorado Blood Cancer Institute, Denver
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Набиране на участнициФаза 2/3
- Colorado Blood Cancer Institute /ID# 279080, Denver
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Набиране на участнициФаза 3
- CBCI, Colorado Blood Cancer Institute, Denver
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 2
- Colorado Blood Cancer Institute, Denver
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 1/2
- Research Site, Denver
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Набиране на участнициФаза 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Набиране на участнициФаза 1/2
- Research Site, Denver
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Набиране на участнициФаза 3
- Research Site, Denver
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Набиране на участнициФаза 1/2
- Colorado Blood Cancer Institute /ID# 273129, Denver
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Набиране на участнициФаза 2
- Colorado Blood Cancer Institute, Denver
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Набиране на участнициФаза 3
- Colorado Blood Cancer Institute, Denver
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Набиране на участнициФаза 2
- Colorado Blood Cancer Institute, Denver
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Набиране на участнициФаза 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Colorado Blood Cancer Institute /ID# 273751, Denver
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Набиране на участнициФаза 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Набиране на участнициФаза 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Colorado Blood Cancer Institute, Denver
Проучвания за Множествен миелом в други градове
- New York City, NY60 проучвания
- Boston, MA42 проучвания
- Atlanta, GA41 проучвания
- Houston, TX38 проучвания
- Durham, NC37 проучвания
- Nashville, TN32 проучвания
- Rochester, MN24 проучвания
- St. Louis, MO24 проучвания
- Columbus, OH24 проучвания
- Baldwin Park, CA23 проучвания
- Chicago, IL22 проучвания
- Seattle, WA22 проучвания
Други проучвания в Denver
- Метастатичен рак29 проучвания
- Рак на гърдата28 проучвания
- Рак на белия дроб с недребноклетъчен тип27 проучвания
- Колоректален рак23 проучвания
- Рак на простатата19 проучвания
- Меланом19 проучвания
- Рак (всички видове)18 проучвания
- Рак на яйчниците16 проучвания
- Рак на белия дроб16 проучвания
- Ендометриален рак15 проучвания
- Нон-Ходжкинов лимфом14 проучвания
- Рак на панкреаса13 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.